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Abstract 
Objective: Type 1 diabetes can be identified by the presence of beta-cell autoantibodies 
that often arise in the first few years of life. The purpose of this perspective is to present the 
case for primary prevention of beta-cell autoimmunity and to provide a study design for its 
implementation in Europe. 
Methods: We examined and summarized recruitment strategies, enrolment rates, and 
outcomes in published TRIGR, FINDIA and BABYDIET primary prevention trials, and the 
TEDDY intensive observational study. A proposal for a recruitment and implementation 
strategy to perform a phase II/III primary prevention randomized controlled trial in infants 
with genetic risk for developing beta-cell autoimmunity is outlined. 
Results: Infants with a family history of type 1 diabetes (TRIGR, BABYDIET, TEDDY) and 
infants younger than age 3 months from the general population (FINDIA, TEDDY) were 
enrolled into these studies. All studies used HLA genotyping as part of their eligibility criteria. 
Predicted beta-cell autoimmunity risk in the eligible infants ranged from 3% (FINDIA, TEDDY 
general population) up to 12% (TRIGR, BABYDIET). Amongst eligible infants, participation 
was between 38% (TEDDY general population) and 97% (FINDIA). Outcomes, defined as 
multiple beta-cell autoantibodies, were consistent with predicted risks. We subsequently 
modeled recruitment into a randomized controlled trial (RCT) that could assess the efficacy 
of oral insulin treatment as adapted from the Pre-POINT pilot trial. The RCT would recruit 
infants with and without a first-degree family history of type 1 diabetes and be based on 
general population genetic risk testing. HLA genotyping and, for the general population, 
genotyping at additional type 1 diabetes susceptibility SNPs would be used to identify 
children with around 10% risk of beta-cell autoimmunity. The proposed RCT would have 
80% power to detect a 50% reduction in multiple beta-cell autoantibodies by age 4 years at a 
two-tailed alpha of 0.05, and would randomize around 1160 infants to oral insulin or placebo 
arms in order to fulfill this. It is estimated that recruitment would require testing of between 
400,000 and 500,000 newborns or infants. 
Conclusion: It is timely and feasible to establish a platform for primary prevention trials for 
type 1 diabetes in Europe. This multi-site European infrastructure would perform RCTs, 
supply data coordination and biorepository, provide cohorts for mechanistic and 
observational studies, and increase awareness for autoimmune diabetes. 
 
Highlights 
• GPPAD is a new type 1 diabetes prevention initiative in Europe. 
• GPPAD will provide infrastructure for trials to reduce beta-cell autoimmunity.  
• An adaptable GPPAD trial with antigen-based therapy is modeled. 
• GPPAD will provide new opportunities for mechanistic and observational studies. 
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1. Introduction 
Type 1 diabetes results from an autoimmune destruction of the insulin-producing beta cells 
within the pancreatic islets of Langerhans. This process is identified by circulating islet 
autoantibodies to beta-cell antigens and is mediated by a lack of immunological self-
tolerance [1, 2]. Self-tolerance is achieved by T cell exposure to self-antigens in the thymus 
or in the periphery (i.e. outside the thymus or bone marrow, in secondary lymphoid tissues 
such as lymph node, gut and spleen) in a manner that deletes autoreactive effector T cells or 
induces regulatory T cells and regulatory cytokines such as interleukin-10 (IL-10). 
Immunological tolerance can be achieved by administration of antigen under appropriate 
conditions [3, 4]. Evidence is now emerging in humans that these approaches may be 
effective in chronic inflammatory diseases such as multiple sclerosis, allergy, and type 1 
diabetes [5-8]. 
GPPAD is the Global Platform for the Prevention of Autoimmune Diabetes that was 
established in 2015 in Germany and UK with the intention to establish an infrastructure for 
primary prevention trials. More specifically, we aim to develop and launch the first 
randomized controlled phase II/III trial (RCT) using autoantigen-based therapy and to 
consider other approaches that might inhibit or prevent the earliest events in newborns that 
lead to multiple anti-islet autoantibodies. GPPAD will also investigate the feasibility, 
practicalities, and acceptability of recruitment of newborn children into mechanistic studies 
and third generation natural history studies. Antigen-based therapy in type 1 diabetes will 
serve as a model system. However, the planned platform will be adaptable and deployable 
in the investigation and prevention of other approaches to type 1 diabetes primary 
prevention, and to other childhood conditions and illnesses, with a major underlying goal of 
the promotion of better health outcomes early in life and during pregnancy based on 
improved understanding of the human immune system. GPPAD will focus on primary 
prevention, defined as the prevention of seroconversion to beta-cell autoantibodies. Primary 
prevention has a strong rationale. First, neonates who are at increased risk to develop 
multiple beta-cell autoantibodies and type 1 diabetes can be identified using family history 
and/or genetic markers at several loci, in particular HLA class II and class I haplotypes. 
Second, there is a marked peak incidence period of beta-cell autoantibody seroconversion 
between age 9 months and 2.5 years, providing a finite study follow-up until age 3-4 years 
and the primary endpoint in a RCT. Third, there is an early autoantibody target, insulin and 
its precursor preproinsulin, encoded by a gene with a common polymorphism that confers 
genetic risk for type 1 diabetes by altering neonatal immune tolerance to insulin and its 
precursors. Primary prevention also offers the opportunity and a platform to have a second 
chance at prevention (secondary) if children develop beta-cell autoantibodies. 
It is widely held that if neonatal tolerance to beta-cell antigens could be enhanced, this could 
prevent or delay the onset of pre- or asymptomatic type 1 diabetes (defined as loss of 
tolerance and multiple autoantibodies) and prevent or delay disease diagnosis. The key here 
is “neonatal”, the time when the natural mechanisms of immune tolerance are fully active as 
the child becomes tolerant to commensal microorganisms and dietary components. 
Currently, antigen-specific tolerance approaches are attempted in individuals in whom the 
immune system has matured and in whom an autoimmune memory response is well 
established. We, however, have laid the foundation for antigen-specific primary prevention 
by demonstrating in genetically at-risk children aged 2-7 years who are beta-cell 
autoantibody negative that orally-delivered insulin is safe (does not affect plasma glucose 
levels) at a dose that appears to engage the immune system in a manner that is consistent 
with immune-mediated, tolerogenic protection [9]. 
Hence, we believe that we have three important pillars for primary prevention to move 
forward – a strategy to identify neonates at type 1 diabetes risk by genetic markers; 
knowledge when beta-cell autoimmunity starts; and demonstration that antigen-specific 
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therapy is feasible. With these in hand, the task is to develop an infrastructure that can make 
a significant impact on reducing the numbers of children who develop type 1 diabetes via 
broad and safe primary prevention therapy. Avenues to achieve the implementation of such 
a program will be discussed. 
 
 
2. Review of previous primary prevention efforts 
2.1  The TRIGR study (Trial to Reduce IDDM in Genetically at Risk) 
The TRIGR study is a dietary randomized controlled trial aiming to reduce the incidence of 
beta-cell autoimmunity and type 1 diabetes by weaning to an extensively hydrolyzed formula 
[10]. The trial was unsuccessful in reducing beta-cell autoimmunity. The study is still ongoing 
to access risk of type 1 diabetes. It has estimated a cumulative incidence of 9.9% by age 6 
years for multiple beta-cell autoantibodies in the control group. The study was powered to 
detect a 35% change in the end point, and 20% risk to miss a true difference between the 
groups. Concurring with initial estimates, the risk of positivity for two or more beta-cell 
autoantibodies was 11.4% (95%CI, 9.4%-13.2%) among those randomized to the control 
group (conventional formula, n = 117), and similarly 13.4% (95%CI, 11.3%-15.5%) among 
those randomized to the casein hydrolysate formula (n = 139). There were no clinically 
significant differences in the rate of reported adverse events between the two groups. 
Although the outcome of TRIGR was disappointing from an efficacy viewpoint, the TRIGR 
study has without doubt an unprecedented value in uniquely demonstrating that conducting 
primary prevention trials for type 1 diabetes is feasible. TRIGR has recruited 2159 infants 
with HLA-conferred disease susceptibility1 and a first-degree relative with type 1 diabetes of 
a total of 5156 (42%) tested for HLA eligibility. Infants were prospectively followed for at least 
6 years with high retention and documented protocol adherence.  
2.2 The BABYDIET pilot study 
The open randomized controlled BABYDIET study aimed to reduce beta-cell autoimmunity 
by delayed gluten exposure in the first year of life [11]. Evidence came from two natural 
history studies, BABYDIAB and the Diabetes and Autoimmunity Study in the Young (DAISY), 
which demonstrated that early gluten exposure is associated with increased risk of beta-cell 
autoimmunity in childhood [12, 13]. Of 1168 newborn children with a first-degree relative with 
type 1 diabetes screened for eligibility, 169 were found eligible because they had the high 
risk HLA genotypes2, and 150 (89%) consented to participate. Participants were followed for 
at least 3 years with 27 children developing beta-cell autoantibodies (cumulative risk by age 
4 years for any beta-cell autoantibody: 15.4% (95%CI, 9.5%-21.3%); for multiple beta-cell 
autoantibodies: 9.5% (95%CI, 4.6%-14.1%). The study demonstrated no beneficial effect of 
delaying gluten exposure to 12 months of age when compared to introducing gluten at 6 
months of age in the intention to treat as well as per protocol analysis. Only 70% of families 
adhered to the dietary-intervention protocol while 30% introduced gluten earlier or later than 
recommended. This study indicates that an open dietary prevention trial is likely to have 
                                                          
1
 DQB1*02/DQB1*03:02; DQB1*03: 02/x (x not DQB1*02, DQB1*03:01, or DQB1*06:02); DQA1*05-DQB1*02/y 
(y not DQA1*02:01-DQB1*02, DQB1*03:01, DQB1*06:02, or DQB1*06:03); DQA1*03-DQB1*02/y (y not 
DQA1*02:01-DQB1*02, DQB1*03:01, DQB1*06:02, or DQB1*06:03) 
 
2
 DRB1*03-DQA1*0501-DQB1*0201/DRB1*04-DQA1*0301-DQB1*0302; 
DRB1*04-DQA1*0301-DQB1*0302/DRB1*04-DQA1*0301-DQB1*0302;  
DRB1*03-DQA1*0501-DQB1*0201/DRB1*03-DQA1*0501-DQB1*0201;  
DRB1*04-DQA1*0301-DQB1*0302/DRB1*08-DQA1*0401-DQB1*0402; 
DRB1*04-DQA1*0301-DQB1*0302/DRB1*01-DQA1*0101 -DQB1*0501 
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limitations with respect to protocol adherence, which in consequence will affect the ability to 
measure efficacy of the intervention. 
2.3 The FINDIA Pilot Study 
The Finnish Dietary Intervention Trial for the Prevention of Type 1 Diabetes (FINDIA) 
recruited 1104 infants with type 1 diabetes susceptible HLA genotypes3 to a randomized 
double-blind three-arm clinical trial aimed at determining whether the removal of bovine 
insulin from infant formula milk reduced the incidence of beta-cell autoimmunity at age 3 
years [14]. The trial was successful in recruiting all children over a 3.5-year period from three 
Finnish pediatric hospitals, with an acceptance rate of 97% of those being found eligible (n = 
1133). Of the randomized children, 908 (82.3%) provided one follow-up sample, and 196 
(17.7%) withdrew from the study; after 3 years of follow-up, around 50% remained in the 
study. The pilot trial found a significant decrease in the prevalence of one or more beta-cell 
autoantibodies in the children who had been assigned to the bovine insulin free formula 
group. 
2.4 TEDDY 
The Environmental Determinants of Diabetes in the Young (TEDDY) study is a longitudinal 
cohort study with the primary aim to identify dietary factors, infectious agents, or other 
environmental exposures associated with an increased risk of islet autoimmunity and type 1 
diabetes [15]. It follows children from age 3 months to age 15 years with intensive 3 to 6 
months follow-up visits and blood draws without any intervention. The TEDDY study 
included children with an increased genetic risk4. TEDDY screened 424,788 newborns for 
eligibility over a period of 6 years including 418,348 from the general population and 6440 
from families with first-degree relatives diagnosed with type 1 diabetes. Of general 
population newborns, 20,133 (4.8%) met the HLA eligibility criteria; of newborns with a first-
degree relative, 1456 (22.6%) were found to be eligible. Of eligible children, 8676 (40.2%) 
families consented to participate in TEDDY and started the long-term follow-up, including 
7724 (38.4%) from the general population, and 952 (65.4%) with a first-degree relative. 
 
 
3. Lessons from previous primary prevention studies in type 1 diabetes 
 Primary prevention trials in first-degree relatives are feasible and multi-center 
recruitment is possible. 
                                                          
3
 DQB1*02/DQB1*0302; DQB1*0302/x (x not DQB1*0301 or DQB1*0602); DQA1*05-DQB1*02 (DR3)/y (y not 
DQB1*0301, DQB1*0602, or DQB1*0603) 
4
 General population: DR4-DQA1*030X-DQB1*03021/DR3-DQA1*0501-DQB1*02 01; DR4-DQA1*030X-
DQB1*03021/DR4-DQA1*030X-DQB1*03021; DR4-DQA1*030X-DQB1*03021/DR8-DQA1*0401-DQB1*0402; 
DR3-DQA1*0501-DQB1*0201/DR3-DQA1*0501-DQB1*0201 (DR4 subtyping must exclude DRB1*0403) 
First-degree relatives: DR4-DQA1*030X-DQB1*03021/DR3-DQA1*0501-DQB1*0201; DR4-DQA1*03 0X-
DQB1*03021/DR4-DQA1*030X-DQB1*03021; DR4-DQA1*030X-DQB1*03021/DR8-DQA1*0401-DQB1*0402; 
DR3-DQA1*0501-DQB1*0201/DR3-DQA1*0501-DQB1*0201; DR4-DQA1*030X-DQB1*03021/DR4-DQA1*030X-
DQB1*020X; DR4-DQA1*030X-DQB1*03021/DR12-DQA1*0101-DQB1*0501; DR4-DQA1*030X-
DQB1*03021/DR13-DQA1*0102-DQB1*0604; DR4-DQA1*030X-DQB1*0302/DR4-DQA1*030X-DQB1*0304; 
DR4-DQA1*030X-DQB1*03021/DR9-DQA1*030X-DQB1*0303; DR3-DQA1*0501-DQB1*0201/DR9-DQA1*030X-
DQB1*0303 
 
(1 = Acceptable alleles in this haplotype include both DQB1*0302 and *0304; 2 = In this DQB1*0501 haplotype, 
DR10 must be excluded. Only DR1 is eligible) 
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 Recruitment to primary prevention trials beyond first-degree relatives based on 
testing for genetic risk is possible.  
 Prevention trials that are non-blinded with open access to treatment arm may lead to 
insufficient protocol adherence. 
 Infants with approximately 10% genetic risk for multiple beta-cell autoimmunity can 
be identified. 
 Acceptance by eligible families to participate in prevention or intensive observational 
studies ranged from 38% to 97%. 
 
 
4. Mechanistic approach to study immune efficacy in primary prevention 
4.1 Pre-POINT 
Antigen-based therapy using oral insulin exposure at a dose of 1 mg twice a week is efficient 
to prevent autoimmune diabetes in NOD mice [16]. Insulin was given from week 5 when 
NOD mice have initial signs of beta-cell inflammation and lymphocytic infiltration. In humans, 
oral insulin therapy at a modest daily dose of 7.5 mg does not delay progression to type 1 
diabetes in first-degree relatives with insulin autoantibodies and ICA with the possible 
exception of a subgroup of relatives with high levels of insulin antibodies where daily 7.5 mg 
oral insulin might delay the clinical onset of type 1 diabetes by an average of 10 years [17]. 
The difference between the mouse and human studies were the timing of treatment and the 
dose, which was estimated to be around 10-fold higher in successfully treated mice. 
The Pre-POINT study is the first to administer an autoantigen to genetically at-risk children 
prior to any signs of autoimmunity [9]. The rationale is to expose oral mucosa to antigen in 
order to stimulate the immune system in a safe environment that normally favors a 
tolerogenic immune response. Thus, the objective of Pre-POINT has been to identify a dose 
of oral insulin that is safe and engages the immune system towards immune tolerance. 
Pre-POINT was performed as a double-blind placebo-controlled dose increasing phase I/II 
clinical trial. Children aged two to seven years with a family history of type 1 diabetes and 
type 1 diabetes susceptible HLA class II genotypes and without islet autoantibodies (n=25) 
were randomized to receive placebo (n=10) or insulin (n=15) orally once a day for 3 to 18 
months. The design included dose escalation so that six children were included in each of 
the 2.5 mg, 7.5 mg, 22.5 mg, and 67.5 mg insulin dose groups. The highest dose was 
estimated to be equivalent to the dose required to prevent diabetes development in NOD 
mice. None of the doses caused hypoglycemia. All doses were well tolerated, and adverse 
events were similar between placebo and insulin treated children. Daily administration of 
67.5 mg of insulin was able to induce a measurable T and/or B cell immune response to 
insulin. The response differs to the typical responses seen in children who develop diabetes 
in that the antibody responses are of weak affinity. Moreover, one child developed salivary 
IgA response to insulin, suggesting a specific response to insulin exposure in the mouth. The 
T cell responses were most informative, with a preponderance of cells showing regulatory T 
cell gene expression. These regulatory gene expression profiles are unique for the 
respective T cells of children treated with the 67.5 mg dose compared to lower doses or 
placebo (Figure 1). These results are encouraging from a safety viewpoint and indicate that 
oral exposure to insulin at doses that are approximately equivalent to efficacious doses in 
rodents may promote tolerance in children. 
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4.2 Learning from peanut allergy 
Around the same time as the Pre-POINT study, a large study aimed at preventing peanut 
allergy through active exposure to antigen were performed and reported. Unlike previous 
attempts based on avoidance of peanuts, the consumption trial was successful, providing 
supporting evidence for antigen-based therapies in disorders such as type 1 diabetes. 
Relevant to primary prevention, the LEAP trial enrolled 542 infants who initially had no 
preexisting sensitivity to peanuts, but who had an estimated 9% risk for developing peanut 
allergy by age 5 years [7]. Children randomized to peanut consumption were instructed to 
eat at least three peanut-containing meals per week in order to consume at least 6 g of 
peanut protein per week until age 5 years. In comparison, children taking the highest oral 
insulin dose in Pre-POINT consumed a total of 0.47 g of insulin per week, which, if one 
assumes that less than 10% of total peanut protein is allergenic, corresponds well to the 
exposure to allergen in the LEAP trial. The prevalence of peanut allergy at 60 months of age 
was 13.7% in children who avoided peanut consumption and, remarkably, only 1.9% in 
children who consumed peanuts (P<0.001). The results are even more striking in a per 
protocol analysis where 0.4% of non-sensitized children developed peanut allergy in the 
consumption group. Interestingly, peanut consumption is followed by the development of 
peanut-specific IgG4 and avoidance by peanut-specific IgE antibody, respectively. T cell 
studies were not reported. Another impressive aspect of the LEAP trial was that only 12 
(2.2%) of the 542 enrolled children did not complete the study at age 5 years. Overall, the 
primary prevention part of the LEAP trial is encouraging for GPPAD attempts to introduce 
autoantigen-based primary prevention for type 1 diabetes. 
4.3 Pre-POINT-Early 
Many children with type 1 diabetes develop beta-cell autoimmunity between 9 months and 
2.5 years of age. Hence, in order to offer possible efficacy in the broadest sense, treatment 
for primary prevention will need to start prior to that age. Pre-POINT-Early is a double-blind 
RCT performed in children aged 6 months to 2 years in order to validate the findings of Pre-
POINT and determine safety of the 67.5 mg dose of insulin in very young children. The study 
was recently initiated in Germany and will recruit and randomize 44 children at a 1:1 ratio to 
daily oral insulin powder ingested with food (dose escalation: 7.5 mg per day for 3 months; 
increased to 22.5 mg per day for 3 months; increased to 67.5 mg per day for 6 months) or 
placebo. Families will self-administer the oral insulin powder packed in capsules. The 
outcome is again a measurable adaptive immune response to insulin that has features of a 
regulatory response and does not have the features associated with beta-cell autoimmunity. 
The trial has 80% power to detect an immune response in 67% of treated children at a two-
tailed significance of 0.05. We reason that if Pre-POINT-Early is able to show such an 
immune response in the absence of safety concerns, there is sufficient rationale to plan a 
phase II/III trial assessing the efficacy of oral insulin administration to prevent beta-cell 
autoimmunity. We expect to have results by January, 2018. 
 
 
5. GPPAD phase II/III RCT and trial platform 
The first GPPAD RCT is currently being planned. The lead therapy is oral insulin with an 
objective to test the efficacy of therapy to reduce the incidence of beta-cell autoimmunity in 
genetically at-risk children. This is under the assumption that results from Pre-POINT-Early 
will demonstrate safety and confirm immune efficacy. The goal is to introduce immune 
tolerance against autoantigen before the start of beta-cell autoimmunity as primary 
prevention for type 1 diabetes. There are several reasons why we favor insulin as one of our 
first choice candidates for primary prevention. There is clear evidence from man [18, 19] and 
animal models [20] that insulin is the key early and primary autoantigen of childhood 
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diabetes. There is also a strong genetic rationale for loss of tolerance against insulin as a 
primary predisposing factor for type 1 diabetes. Allelic variation in the insulin gene is 
associated with type 1 diabetes [21] and islet autoimmunity [22] via a mechanism of thymic T 
cell deletion [23]. Moreover, insulin autoimmunity is closely associated with the HLA DR4-
DQ8 haplotype present in over 60% of children who develop type 1 diabetes. There are also 
practical considerations, given the excellent safety profile thus far whereby both, antibody 
and T cell immune responses can be directly measured and serve as biomarkers of immune 
efficacy. 
GPPAD will, however, be mindful of alternative approaches. For example, we are aware of 
increasing evidence for a role of vitamin D in immune tolerance [24], and we will consider 
mechanistic studies and development of therapies such as proinsulin peptides [25], insulin 
mimetopes [26], nasal insulin [27], or probiotics [28] and anti- or pro-inflammatory seasonal 
therapy [29]. The promise is to develop a platform for multiple studies. This platform should 
include the neonate and infant testing sites and centers, a data coordinating center that 
provides data base, data analysis, biorepository, and procedures for regulatory approval, a 
pharmacy, and a communication and dissemination center. 
5.1 Target age and population 
Infants will be recruited. Start of treatment will not be before the introduction of solid foods, 
which is usually between age 4 and 6 months. Since there is a marked rise in beta-cell 
autoantibody seroconversion, and in particular insulin autoantibody seroconversion at 
around age 9-12 months of age, and a lower incidence of insulin autoimmunity beyond this 
age [30-32], we suggest that the trial target children below age 9 months. It is noted that a 
beta-cell autoimmunity can start already at age 6 months in a small minority (<5%) of 
children who develop type 1 diabetes [30-32]. 
Participants will be required to have an HLA-DR4/HLA-DQ8 haplotype and have an 
estimated genetic risk of at least 10%, which can be achieved in several ways: 1. A multiple 
first-degree family history of type 1 diabetes [33]; 2. A first-degree relative of a patient with 
type 1 diabetes, a HLA-DR4/HLA-DQ8 haplotype and no protective HLA-DR or HLA-DQ 
haplotypes; 3. No first-degree family history of type 1 diabetes, but a combined genetic risk 
score that we expect corresponds to the upper 0.5% of the general population. This risk 
score was estimated using T1DGC data [34] and will be refined in much larger cohort of non-
diabetic individuals and using data from patients not selected because they have a first-
degree relative with type 1 diabetes, that is population-based, prior to finalizing the trial 
protocol. 
The RCT will have two recruitment phases (Figure 2). The first phase will only include first-
degree relatives of patients with type 1 diabetes who fulfill the 10% risk criteria. The purpose 
of this is to extend safety data in infants and to provide a run in period for logistics of the 
study. It will run for a period of 12 months and is expected to recruit 100 infants to the RCT. 
The second recruitment phase will extend eligibility to all three categories and include infants 
without a family history of type 1 diabetes. 
5.2 Testing for diabetes genetic risk 
Newly born babies in Europe are routinely screened within the first days after birth, using a 
few drops of blood from the heel onto filter paper cards, for certain genetic, endocrine, and 
metabolic disorders, and are also tested for hearing loss prior to discharge from a hospital or 
birthing center. Depending on the country, additional information such as the baby’s name, 
sex, weight, date/time of birth, date/time of heel stick collection, and date/time of first 
feeding, and contact information of the parents and the baby’s primary care physician is also 
collected. 
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Testing for type 1 diabetes genetic risk for eligibility into the RCT will be done via filter paper 
cards, which will be separate from the official newborn screening cards, and offered to 
families either together with the established newborn screening as supplemental testing with 
separate consent, or will be offered at regular child check-ups performed at the primary care 
pediatrician at the age of 3-10 days (U2), 4-5 weeks (U3), or 3-4 months (U4). Information 
about type 1 diabetes in the family will be obtained. Supplemental diabetes risk assessment 
and the subsequent possibility to participate in a RCT to prevent diabetes in case of higher 
genetic risk and any concerns will be discussed with the families. Diabetes risk assessment 
will be financed through research and will be of no cost for the family. 
Genetic testing will be first surveyed in Saxony, Germany, with trial centers in Dresden and 
Leipzig; additional testing and trial centers in Germany (Hannover in Lower Saxony, Munich 
in Bavaria); Saxony covers around 36,000 births per year, Lower Saxony 66,000, and 
Bavaria 110,000. Testing in the UK, and potentially other European countries will follow. 
5.3 Genetic eligibility and testing 
Genetic testing will be performed by a two-step process. The first is based on HLA and 
family history of type 1 diabetes. HLA will be determined by three SNPs to identify 1. Infants 
who have the HLA DR4-DQ8 haplotype amongst first-degree relatives of patients; and 2. All 
infants, regardless of their type 1 diabetes family history, who have the HLA DR3/DR4-DQ8 
or DR4-DQ8/DR4-DQ8 genotype [35]. Relatives with HLA DR4-DQ8 will then be tested for 
the protective alleles DRB1*0403, DR11, DR12, DQB1*0602, DR7-DQB1*0303, DR14-
DQB1*0503, DRB1*13-DQB1*0603 and will be eligible if none of these are present; outcome 
risk is estimated to be 12%. Non-relatives with the HLA DR3/DR4-DQ8 or DR4-DQ8/DR4-
DQ8 genotypes will be tested with a panel of SNPs from HLA class I and non-HLA class II 
regions to identify infants with a predicted outcome risk of around 10%. The SNP panel is in 
development and will be based on algorithms similar to those described [34, 36]. Genetic 
typing will be outsourced. 
5.4 Outcome 
The primary outcome of the RCT is multiple beta-cell autoantibodies, or type 1 diabetes, at 
the age of 4 years. Multiple beta-cell autoantibody positive is defined as antibodies against 
two or more beta-cell antigens - insulin, GAD65, IA-2, ZnT8 – in two consecutive samples. 
5.5 RCT size and statistical power 
It is estimated that 11% of the placebo-treated children will develop multiple beta-cell 
autoantibodies. In order to have 80% power to detect a 50% reduction in risk of beta-cell 
autoimmunity with two-tailed alpha of 0.05, 521 children are required in each arm. With an 
expected drop-out rate of 10%, 1158 infants will need to be enrolled into the RCT. 
5.6 Design 
The oral-insulin-RCT will be conducted in two recruitment phases (Figure 2). 
The first recruitment phase will be restricted to infants who are first-degree relatives of 
patients with type 1 diabetes and will last 12 months. The target of genetic testing in this 
phase is 500 infants. Around 30% of all first-degree relatives are estimated to meet eligibility 
criteria and around 50% are expected to participate in the RCT. Thus, recruitment of around 
75 infants is expected in this phase. Based upon the prevalence of type 1 diabetes in 
Germany, 0.8 to 1% of all newborns will have a parent or sibling with type 1 diabetes. Thus, 
around 60,000 births would be required to reach the target in the first recruitment phase. 
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The second recruitment phase will target all newborns within the genetic testing sites. We 
estimate that this will require an additional 400,000 newborns to be tested in order to reach 
the final target of 1158 participants in the RCT. This estimate is based on the assumptions 
that 1% (4000) of newborns are first-degree relatives of patients with type 1 diabetes, that 
30% (1200) of these will be eligible and that 50% (600) will accept to be randomized, and 
that 0.5% (1980) of the newborns without a relevant family history will have an eligible 
genetic risk score and that 30% (594) of these will participate. Acceptance rates are 
estimated from the TRIGR and TEDDY relatives and on the basis that acceptance to 
participate in general population eligible infants was around 60% of the acceptance amongst 
the eligible first-degree relatives. These numbers are likely to require adjustment as the RCT 
proceeds but provide a feasible target and a guideline to the effort required to conduct a 
phase II/III primary prevention RCT. 
5.7 Treatment 
Infants will be treated with daily placebo or daily oral insulin at a dose of 7.5 mg for 2 
months, followed by a dose of 22.5 mg for 2 months, and followed by a dose of 67.5 mg, 
which will be given until they reach age 4 years. Children who develop multiple islet 
autoantibodies have reached the primary trial outcome and will stop treatment. The amount 
of insulin required per child is around 80 g for 3.5 years of treatment. Around 50 kg of insulin 
crystals will be needed to complete the trial. 
5.8 Opportunities arising from the RCT 
A number of opportunities arise from establishing the platform to conduct such a RCT. First, 
there will be the opportunity to enroll families that do not wish to participate in the oral insulin 
RCT into observational studies or mechanistic studies. These could include mechanistic 
studies that contain intervention protocols such as dietary supplements. Important for these 
studies will be the opportunity to collect samples that can be used to examine cellular 
immune responses in the first year of life, a resource that is currently rarely available. The 
platform could also serve to validate findings from the TEDDY study with respect to 
environmental exposures that may associate with beta-cell autoimmunity. Finally, the design 
of the oral insulin RCT excludes infants who are HLA-DR3/DR4-DQ8 or DR4-DQ8/DR4-
DQ8, but do not reach a 10% outcome risk. These are nearly 2% of the tested population 
and will have an outcome risk of around 3%, which is sufficiently high to consider other 
interventions such as dietary supplements. Moreover, children who reach the outcome and 
become multiple beta-cell autoantibody positive could be eligible for trials to revert 
autoimmunity and prevent progression to clinical hyperglycemia. Thus, the platform would 
provide a pipeline for multiple parallel primary prevention trials and treatment trials. 
5.9 Significance 
It is understood that GPPAD has a long-term and multifaceted vision of how to achieve type 
1 diabetes prevention and intervention, and that the first RCT and trial platform will be one 
important component of this vision. If successful, the program will provide the strategy and 
infrastructure to introduce prevention at the level and scale needed to quickly assess 
efficacy and quickly integrate successful prevention at the population level. Beyond this, the 
GPPAD program will increase awareness for autoimmune diabetes and its early diagnosis, 
and as such has the potential to improve care of children at diabetes risk. The platform may 
also serve as a model for other childhood diseases. 
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5.10. Roadblocks of primary prevention 
There are challenges and roadblocks which may impede the successful implementation of 
primary prevention strategies including costs, public awareness, feasibility, and limited 
evidence of successful therapy. 
The costs for primary prevention RCTs are high, and likely to be considerably higher than 
performing trials in children with established beta-cell autoimmunity. Our unofficial estimate 
is in the tens of millions of euro for the trial outlined in Figure 2. Part of the reason for the 
high costs is that even though type 1 diabetes risk in the participating children is at least 20-
fold higher than background, we are forced to treat a large number of children who will not 
develop diabetes. This underlines the need for biomarkers that go beyond genetic 
susceptibility, and can discriminate infants with higher risk than what can be realized with 
genotyping. Feasibility of recruitment and follow-up during infancy and early childhood has 
been established in previous studies (see sections 2. and 3.). However, experience from 
these studies indicates that large resources need to be invested into education, awareness, 
compliance and retention in order achieve this. Thus, the efforts and expenditure required for 
conducting a primary RCT call for a larger return for the investment. GPPAD will achieve this 
by integrating the RCT into a platform of mechanistic studies and natural history studies 
which not only aims to test multiple prevention strategies but also collect precious 
biomaterial to provide novel insights into disease pathogenesis and biomarker development 
to meet the changing needs of the scientific and clinical community with respect to reducing 
the incidence of type 1 diabetes. Related to this is the awareness that, while we present 
evidence as to why antigen-based therapies with insulin could be tested in a RCT, there are 
no efficacy data for primary prevention with oral insulin or any other antigen-specific therapy. 
Again, the benefit of the platform is the effort is not solely focused on successful prevention 
with a single RCT, but to include multiple short-term increments in knowledge and a long-
term infrastructure for implementing prevention therapeutics. 
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Figure Legends 
Figure 1. CD4+ T cell immune response profiles against insulin from the Pre-POINT trial [9]. 
Multivariate gene expression analysis of insulin-responsive CD4+ T cells isolated from Pre-
POINT participants with CD4+ T cell responses to insulin. The data show t-distributed 
Stochastic Neighbor Embedding (tSNE) analysis of pre-processed Ct values for all analyzed 
genes. A linear model was used to correct for confounding effects, which can mask relevant 
biological variability. Batch effects (dummy coding each plate/batch) were modeled jointly 
with dose effects to obtain a corrected gene expression data set. This resulted in two distinct 
clusters, with one cluster consisting of cells derived from children receiving 67.5 mg insulin 
(green symbols) and the second cluster consisting of cells derived from children receiving 
placebo (blue symbols), 2.5 mg insulin (red symbols), 7.5 mg insulin (yellow symbols), and 
22.5 mg insulin (purple symbols). C1, C2, and C3 are component 1, component 2, and 
component 3 of the tSNE. Reproduced from reference #9 with permission from JAMA 
American Medical Association (License Number 3786541433624). 
 
Figure 2. Design of GPPADT1PI randomized controlled trial. 
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